Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs

Oncology Reports

Volumn 31, Issue 3, 2014, Pages 1437-1444

  Wang, Yuqian ^a   Liu, Chenlu ^a   Xia, Qiu ^a   Wang, Peng ^a   Li, B O ^a   Lu, Zhenzhen ^a   Sun, Jiaxi ^a   Wu, Hui ^a   Yu, Bin ^a   Wu, Jiaxin ^a   Yu, Xianghui ^a   Kong, Wei ^a   Zhang, Haihong ^a   Cong, Xianling ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

DDA MPL; Melanoma; MUC1 VNTRs; Vector prime protein boost

Indexed keywords

CANCER VACCINE; DIMETHYLDIOCTADECYLAMMONIUM BROMIDE; GAMMA INTERFERON; MUCIN 1; MUCIN 1 VPP VACCINE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CANCER SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; VACCINE PRODUCTION;

ADENOVIRIDAE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENETIC VECTORS; IMMUNITY, HUMORAL; LIPID A; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MINISATELLITE REPEATS; MUCIN-1; NEOPLASM TRANSPLANTATION; QUATERNARY AMMONIUM COMPOUNDS; VACCINATION;

EID: 84896733373     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2950     Document Type: Article

References (21)

1. Tang CK and Apostolopoulos V: Strategies used for MUC1 immunotherapy: preclinical studies. Expert Rev Vaccines 7: 951-962, 2008.
2. Tang CK, Katsara M and Apostolopoulos V: Strategies used for MUC1 immunotherapy: human clinical studies. Expert Rev Vaccines 7: 963-975, 2008.
3. Snyder LA, Goletz TJ, Gunn GR, et al: A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice. Vaccine 24: 3340-3352, 2006.
4. Tarp MA, Sorensen AL, Mandel U, et al: Identification of a novel cancer-specific immunodominant glycopeptide epitope in the MUC1 tandem repeat. Glycobiology 17: 197-209, 2007. (Pubitemid 46152536)
5. Yuan S, Shi C, Lv Y, Wang T, Wang H and Han W: A novel Bacillus Calmette-Guérin-based breast cancer vaccine that coexpresses multiple tandem repeats of MUC1 and CD80 breaks the immune tolerance and inhibits MUC1-positive breast cancer growth. Cancer Biother Radiopharm 24: 607-613, 2009.
6. Mukherjee P, Basu GD, Tinder TL, et al: Progression of pancreatic adenocarcinoma is significantly impeded with a combination of vaccine and COX-2 inhibition. J Immunol 182: 216-224, 2009.
7. Nicholls EF, Madera L and Hancock RE: Immunomodulators as adjuvants for vaccines and antimicrobial therapy. Ann NY Acad Sci 1213: 46-61, 2010.
8. Korsholm KS, Agger EM, Foged C, et al: The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 121: 216-226, 2007. (Pubitemid 46663090)
9. Persing DH, Coler RN, Lacy MJ, et al: Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol 10: S32-S37, 2002.
10. Takeuchi O, Hoshino K, Kawai T, et al: Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11: 443-451, 1999. (Pubitemid 29504199)
11. Wang YQ, Zhang HH, Liu CL, et al: Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine melanoma model. Int Immunopharmacol 17: 9-17, 2013.
12. Harari A, Bart PA, Stohr W, et al: An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med 205: 63-77, 2008. (Pubitemid 351185716)
13. Magalhaes I, Sizemore DR, Ahmed RK, et al: rBCG induces strong antigen-specific T cell responses in rhesus macaques in a prime-boost setting with an adenovirus 35 tuberculosis vaccine vector. PLoS One 3: e3790, 2008.
14. Garcia-Hernandez Mde L, Gray A, Hubby B and Kast WM: In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res 67: 1344-1351, 2007.
15. Yu B, Zhang Y, Zhan Y, et al: Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive anti-tumor effects. Oncol Rep 26: 255-264, 2011.
16. You Q, Jiang C, Wu Y, et al: Subcutaneous administration of modified vaccinia virus Ankara expressing an Ag85B-ESAT6 fusion protein, but not an adenovirus-based vaccine, protects mice against intravenous challenge with Mycobacterium tuberculosis. Scand J Immunol 75: 77-84, 2012.
17. Yu H, Karunakaran KP, Jiang X, Shen C, Andersen P and Brunham RC: Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice. Infect Immun 80: 1510-1518, 2012.
18. Kolibab K, Parra M, Yang AL, Perera LP, Derrick SC and Morris SL: A practical in vitro growth inhibition assay for the evaluation of TB vaccines. Vaccine 28: 317-322, 2009.
19. de Gruijl TD and van de Ven R: Chapter six - Adenovirus-based immunotherapy of cancer: promises to keep. Adv Cancer Res 115: 147-220, 2012.
20. Cheever MA, Allison JP, Ferris AS, et al: The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15: 5323-5337, 2009.
21. Lu S: Heterologous prime-boost vaccination. Curr Opin Immunol 21: 346-351, 2009.